Veronese S M, Gambacorta M
Istituto di Anatomia Patologica, Ospedale di Niguarda, Milan, Italy.
Am J Clin Pathol. 1991 Jan;95(1):30-4. doi: 10.1093/ajcp/95.1.30.
In situ determination of proliferative activity was performed on 203 breast cancers by use of Ki-67 monoclonal antibody and immunohistochemical methods. Tumor proliferation rate was analyzed and correlated to tumor size and nodal status. The relationship between Ki-67 proliferative activity and nuclear estrogen receptor content was also investigated on adjacent tissue sections. Ki-67 values ranged from 1 to 75%, with a median value of 10%. Premenopausal patients had greater Ki-67 values (median value, 14.1%) than postmenopausal ones (median value, 9.8%). The authors observed no correlation with lymph nodal involvement, whereas a statistically significant relationship with tumor size was found (P less than 0.01). An inverse correlation (Spearman's coefficient = -0.56; P less than 0.001) was seen between Ki-67 values and nuclear estrogen receptor content. These results, similar to those reported for other kinetic measurements, suggest that in situ detection of Ki-67 proliferation rate is a useful method for obtaining cell cycle information. Follow-up studies will be needed to assess an eventual prognostic relevance.
采用Ki-67单克隆抗体和免疫组化方法对203例乳腺癌进行原位增殖活性测定。分析肿瘤增殖率，并将其与肿瘤大小和淋巴结状态相关联。同时在相邻组织切片上研究Ki-67增殖活性与核雌激素受体含量之间的关系。Ki-67值范围为1%至75%，中位数为10%。绝经前患者的Ki-67值（中位数为14.1%）高于绝经后患者（中位数为9.8%）。作者观察到Ki-67值与淋巴结受累情况无相关性，而与肿瘤大小存在统计学显著关系（P<0.01）。Ki-67值与核雌激素受体含量之间呈负相关（Spearman系数=-0.56；P<0.001）。这些结果与其他动力学测量报告的结果相似，表明原位检测Ki-67增殖率是获取细胞周期信息的一种有用方法。需要进行随访研究以评估其最终的预后相关性。
